Q9970 – Injection, ferric carboxymaltose, 1mg
HCPCS Level II code · Q codes: Temporary Codes
HCPCS codeQ9970
- Long description
- Injection, ferric carboxymaltose, 1mg
- Short description
- Inj ferric carboxymaltos 1mg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1EOther drugs- Added
- July 1, 2014
- Last change
- January 1, 2015 – No change
- Termination date
- December 31, 2014
Frequently asked questions
What is HCPCS code Q9970?
Q9970 is a HCPCS Level II code for injection, ferric carboxymaltose, 1mg. It was discontinued on December 31, 2014.
Does Medicare cover Q9970?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby Q codes
- Q9962 – High osmolar contrast material, 300-349 mg/ml iodine concentration, per ml
- Q9963 – High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml
- Q9964 – High osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml
- Q9965 – Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml
- Q9966 – Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml
- Q9967 – Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
- Q9968 – Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg
- Q9969 – Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose
- Q9972 – Injection, epoetin beta, 1 microgram, (for esrd on dialysis)
- Q9973 – Injection, epoetin beta, 1 microgram, (non-esrd use)
- Q9974 – Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg
- Q9975 – Injection, factor viii fc fusion protein (recombinant), per iu
- Q9976 – Injection, ferric pyrophosphate citrate solution, 0.1 mg of iron
- Q9977 – Compounded drug, not otherwise classified
- Q9978 – Netupitant 300 mg and palonosetron 0.5 mg
- Q9979 – Injection, alemtuzumab, 1 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.